SCHEMBL2398152

SCHEMBL2398152

Clc1cccc(Cn2cnnc2-c2ccc3[nH]cnc3c2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCTL Q9NXS2 5/20 0.58
ACP1 P24666 1/20 0.48
BRD4 O60885 1/20 0.42
P2RX7 Q99572 3/20 0.40
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40
HTR6 P50406 2/20 0.39
JAK2 O60674 1/20 0.39
ROCK2 O75116 1/20 0.39
KDR P35968 1/20 0.39
GSK3B P49841 1/20 0.39
AURKB Q96GD4 1/20 0.39
DBH P09172 1/20 0.39
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
GLA P06280 1/20 0.38
HTT P42858 1/20 0.38
UBE2N P61088 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395188 0.90 QPCTL (0.59) QPCTLACP1BRD4P2RX7PRMT5
SCHEMBL2397290 0.90 QPCTL (0.68) QPCTLACP1P2RX7PRMT5WDR77
SCHEMBL2399845 0.89 QPCTL (0.63) QPCTLACP1BRD4P2RX7PRMT5
SCHEMBL2395959 0.86 QPCTL (0.66) QPCTLBRD4P2RX7PRMT5WDR77
SCHEMBL2397632 0.85 QPCTL (0.62) QPCTLBRD4P2RX7PRMT5WDR77
SCHEMBL2396678 0.84 QPCTL (0.66) QPCTLACP1P2RX7SMN1; SMN2
SCHEMBL2398147 0.84 QPCTL (0.66) QPCTLBRD4PRMT5WDR77HTT
SCHEMBL2396775 0.83 QPCTL (0.57) QPCTLPRMT5WDR77
SCHEMBL2398286 0.83 QPCTL (0.62) QPCTLP2RX7PRMT5WDR77ROCK2
SCHEMBL2397189 0.83 QPCTL (0.66) QPCTLACP1P2RX7PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP claimed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US claimed
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP disclosed
EP-2542549-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2016-05-11 EP disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
US-20110224259-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-15 US disclosed
WO-2011107530-A2 NOVEL INHIBITORS PROBIODRUG AG (DE) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224259-A1 NOVEL INHIBITORS QPCT, GLUL, GLS QPCTL 5/4885ACP1 967/4885BRD4 2162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.